Related Experiment Video
Updated: Jul 2, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
STAT3 phosphorylation inhibitor Bt354 exhibits anti-neoplastic activity in glioblastoma multiforme cells
Yi-Chun Chiang1, Padhmavathi Selvam2, You-Xuan Liu2
1Department of Surgery, Division of Neurosurgery, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
Abstract:
The high mortality rate of glioblastoma multiforme (GBM), a lethal primary brain tumor, is attributable to postsurgical recurrence. STAT3, an oncogenic protein, is a signal transducer and transcription activator encourages cancer cell migration and proliferation, which results in resistance to therapy. STAT3 inhibition reduces cancer metastasis and improves patient prognosis. Bt354, a small molecule STAT inhibitor, exhibits significant cytotoxic and anti-proliferative activities against certain cancer types. Here, we demonstrated that exposure of GBM cells (U87 MG) to Bt354 had a significant, concentration-dependent growth suppression. Bt354 also induced apoptosis and downregulated the expression of the epithelial-mesenchymal transition genes. Therefore, this study suggests the potential of Bt354 for treating GBM owing to its ability to induce cytotoxicity.
Insights
Bt354, a STAT inhibitor, significantly suppressed glioblastoma multiforme (GBM) cell growth, induced cell death, and reduced cancer-promoting gene expression, offering potential for GBM treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glioblastoma multiforme (GBM) has a high mortality rate due to postsurgical recurrence.
- Signal transducer and activator of transcription 3 (STAT3) is an oncogenic protein promoting cancer cell migration, proliferation, and therapeutic resistance.
- STAT3 inhibition is a promising strategy to reduce cancer metastasis and improve patient outcomes.
Purpose of the Study:
- To investigate the efficacy of Bt354, a novel small molecule STAT inhibitor, against GBM cells.
- To evaluate the impact of Bt354 on GBM cell growth, apoptosis, and epithelial-mesenchymal transition (EMT) gene expression.
Main Methods:
- Exposure of U87 MG GBM cells to varying concentrations of Bt354.
- Assessment of cell viability, proliferation, and apoptosis.
- Quantification of epithelial-mesenchymal transition gene expression.
Main Results:
- Bt354 demonstrated significant, concentration-dependent growth suppression in U87 MG GBM cells.
- Bt354 treatment induced apoptosis in GBM cells.
- Downregulation of epithelial-mesenchymal transition genes was observed following Bt354 exposure.
Conclusions:
- Bt354 exhibits significant cytotoxic and anti-proliferative effects on GBM cells.
- Bt354's ability to induce apoptosis and downregulate EMT genes suggests its therapeutic potential for GBM.
- Further research into Bt354 as a GBM treatment is warranted.
